My research interests in the past have included the application of OMIC technologies for the identification of novel urinary biomarkers of renal disease. In the past I have utilized Proteomic, Genomic and Metabolomic techniques to identify candidate biomarkers for further validation in clinical cohorts collected in conjunction with Beaumont Hospital and St Vincent's hospital. I am also interested in the role of the cilia in renal injury or disease; and I am particularly interested in the cilia as an untapped source of urinary biomarkers. I am currently working as part of the international SmartNanoTox project, a horizon 2020 project concerned with gaining a better understanding of the mechanisms of toxicity associated with inhaled nanoparticles in order to identify properties of concern for new nanomaterials, with the aim of reducing the need for blanket toxicity and extensive animal testing in the future. My research focus as part of this collaboration is the establishment of new methods for the analysis of nanomaterials isolated from BALF and tissue samples by mass spectrometry.